Dehydroaripiprazole

Dehydroaripiprazole (OPC-14857) is an active metabolite of Aripiprazole and dopamine D2/D3 receptor partial agonist. Dehydroaripiprazole also has certain affinity for serotonin 5-HT1A, 5-HT2A and 5-HT2B receptors. Dehydroaripiprazole has antipsychotic activity equivalent to Aripiprazole[1][2][3][4][5][6][7][8].

129722-25-4

OPC-14857; DM-14857

12352005

H302, H315, H319, H335

5-HT Receptor; Dopamine Receptor

Reference compound

GPCR/G Protein; Neuronal Signaling

Neuroscience-Neuromodulation

Neurological Disease

https://www.medchemexpress.com/dehydroaripiprazole.html

99.95

DMSO : 20 mg/mL (ultrasonic)

O=C1NC2=C(C=CC(OCCCCN3CCN(C4=CC=CC(Cl)=C4Cl)CC3)=C2)C=C1

C23H25Cl2N3O2

446.37

H302, H315, H319, H335

[6]Tadori Y, et al. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. Eur J Pharmacol. 2011 Oct 15;668 (3) :355-65. |[7]Nagasaka Y, et al. Impact of genetic deficiencies of P-glycoprotein and breast cancer resistance protein on pharmacokinetics of aripiprazole and dehydroaripiprazole. Xenobiotica. 2014 Oct;44 (10) :926-32.|[8]Picada JN, et al. Neurobehavioral and genotoxic parameters of antipsychotic agent aripiprazole in mice. Acta Pharmacol Sin. 2011 Oct;32 (10) :1225-32.|[1]Kirschbaum KM, et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry. 2008;9 (3) :212-8.|[2]Lin SK, et al. Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia. J Clin Psychopharmacol. 2011 Dec;31 (6) :758-62.|[3]Hui-ChingHuang, et al. Detection and quantification of aripiprazole and its metabolite, dehydroaripiprazole, by gas chromatography–mass spectrometry in blood samples of psychiatric patients. Journal of Chromatography B. Volume 856, Issues 1-2, 1 September 2007, Pages 57-61.|[4]Stip E, Tourjman V. et al. Aripiprazole in schizophrenia and schizoaffective disorder: A review. Clin Ther. 2010;32 Suppl 1:S3-20.|[5]Nagasaka Y, et al. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier. Biopharm Drug Dispos. 2012 Sep;33 (6) :304-15.

Room Temperature

4°C (Powder, protect from light)

Reference compound1

No Development Reported